<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546817</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-440</org_study_id>
    <nct_id>NCT02546817</nct_id>
  </id_info>
  <brief_title>Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS</brief_title>
  <official_title>Eliquis (Apixaban) Regulatory Postmarketing Surveillance In Real World Practice (rPMS) For Venous Thromboembolism (VTE) Treatment And Prevention Of Recurrent VTE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the real-world safety/effectiveness of Eliquis in Korean venous thromboembolism&#xD;
      (VTE) patients and patient characteristics that are associated with bleeding among patients&#xD;
      taking Eliquis. To identify factors that might be associated with the safety and&#xD;
      effectiveness profile in Korean VTE patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">September 29, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Safety of Eliquis in Korean VTE patients based on incidence of adverse events (AEs), serious adverse events (SAEs)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient characteristics that are associated with bleeding among patients taking Eliquis</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Patient Characteristics: Age, sex, weight, height, baseline blood pressure, baseline serum creatinine, baseline creatinine clearance, and device insertion history</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Eliquis in Korean VTE patients based on proportion of patients with no evidence of VTE and occurrence of VTE</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>For VTE treatment: The proportion of patients with recurrent VTE at 24 weeks will be calculated. The incidence proportion will be estimated&#xD;
For prevention of recurrent VTE: The proportion of patients with recurrent VTE at 24 weeks, 52 weeks, and 104 weeks, will be calculated. The incidence proportion will be estimated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Eliquis in Korean VTE patients based on proportion of patients with no evidence of VTE and occurrence of VTE</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>For VTE treatment: The proportion of patients with recurrent VTE at 24 weeks will be calculated. The 95% confidence intervals will be estimated&#xD;
For prevention of recurrent VTE: The proportion of patients with recurrent VTE at 24 weeks, 52 weeks, and 104 weeks, will be calculated. The 95% confidence intervals will be estimated</description>
  </secondary_outcome>
  <enrollment type="Actual">29</enrollment>
  <condition>Venous Thromboembolism</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (≥19 years of age) patients who are initiating treatment with Eliquis for the&#xD;
        treatment of VTE or prevention of recurrent VTE for the first time&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (≥19 years of age) patients who are initiating treatment with Eliquis for the&#xD;
             treatment of VTE or prevention of recurrent VTE for the first time in accordance with&#xD;
             the Korean package insert will be enrolled in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prior treatment with Eliquis before enrollment in this study&#xD;
&#xD;
          -  Patients receiving Eliquis treatment for an indication not approved indication in&#xD;
             Korea&#xD;
&#xD;
          -  Patients meeting any of the following criteria will not be included in the study:&#xD;
&#xD;
             i) Hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
        ii) Clinically significant active bleeding&#xD;
&#xD;
        iii) Hepatic disease associated with coagulopathy and clinically relevant bleeding risk&#xD;
&#xD;
        iv) Patients with increased bleeding risk due to such as following diseases:&#xD;
&#xD;
          1. Recent gastrointestinal ulceration history&#xD;
&#xD;
          2. Recent intracranial or intracerebral haemorrhage history&#xD;
&#xD;
          3. Intraspinal or intracerebral vascular abnormalities&#xD;
&#xD;
          4. Recent brain, spinal or ophthalmic surgery history&#xD;
&#xD;
          5. Recent brain or spinal injury&#xD;
&#xD;
          6. Known or suspected oesophageal varices&#xD;
&#xD;
          7. Arteriovenous malformations&#xD;
&#xD;
          8. Vascular aneurysms&#xD;
&#xD;
          9. Patients with malignant neoplasms at high risk of bleeding&#xD;
&#xD;
               -  Concomitant treatment with any other anticoagulant agent:&#xD;
&#xD;
        i) Unfractionated heparin (UFH)&#xD;
&#xD;
        ii) Low molecular weight heparins (enoxaparin, dalteparin, etc)&#xD;
&#xD;
        iii) Heparin derivatives (fondaparinux, etc)&#xD;
&#xD;
        iv) oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc) except under the&#xD;
        circumstances of switching therapy to or from apixaban or when UFH is given at doses&#xD;
        necessary to maintain a patent central venous or arterial catheter&#xD;
&#xD;
          -  Patients with rare hereditary problems of galactose intolerance, the Lapp lactose&#xD;
             deficiency or glucose-galactose malabsorption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Tx</keyword>
  <keyword>Prevent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

